Learn more about whether Generate Biomedicines, Inc. is a good stock to buy or sell based on recent news as well as its key financial metrics. Read on to find out how (GENB) grades on certain investment factors and determine whether it meets your investment needs.

Latest Generate Biomedicines, Inc. Stock News

As of August 20, 2026, Generate Biomedicines, Inc. had a $2.1 billion market capitalization, putting it in the 54th percentile of companies in the Biotechnology industry.

Generate Biomedicines, Inc. does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Generate Biomedicines, Inc.’s trailing 12-month revenue is $26.5 million with a -897.7% profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-2.300 per share for the current fiscal year. Generate Biomedicines, Inc. does not currently pay a dividend.



Sign Up to Receive a Free Special Report That Shows How A+ Investor Grades Can Help You Make Investment Decisions

Grading Generate Biomedicines, Inc. Stock

Before you choose to buy, sell or hold Generate Biomedicines, Inc. stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. To help individual investors decide whether or not to buy (GENB) stock, AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way that is suitable for investors of all knowledge levels.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings revisions and quality. Here, we’ll take a closer look at Generate Biomedicines, Inc.’s stock grades for value, growth and quality. Learn more about A+ Investor here!

Don’t Miss Your Free Report — Sign Up Here!

Generate Biomedicines, Inc. Stock Earnings Estimate Revisions Grade

The Earnings Estimate Revisions Score considers the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. The Earnings Estimate Revisions Score is based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Generate Biomedicines, Inc. has an Earnings Estimate Revisions Score of 26, which is Negative.

Other Generate Biomedicines, Inc. Stock Grades

In addition to Estimate Revisions, A+ Investor also provides grades for Value, Growth, Momentum and Quality.

The Momentum Grade helps uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower—growth companies. AAII measures several dimensions of growth in its Growth Grade, including year—over—year increases in sales and earnings, long(er)—term historical sales and earnings growth rates and analyst‐forecasted long—term earnings growth.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the Quality Grade is the percentile rank of the composite return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F—Score.

These 4 key factors, when combined with the above, provide a holistic view into a stock. Further, by joining A+ Investor you can see whether Generate Biomedicines, Inc.’s stock passes any of our 60+ stock screens that have outperformed the market since their creation.

Should I Buy Generate Biomedicines, Inc. Stock?

Overall, Generate Biomedicines, Inc. stock has a Earnings Estimate Revisions Grade of D.

Whether or not you should buy Generate Biomedicines, Inc. stock will ultimately depend on your individual goals, risk tolerance and allocation. AAII can help you figure these out and identify which investments align with what works best for you.

Lastly, it’s important to evaluate a stock by comparing it against others in the same industry. Review the table below to see how Generate Biomedicines, Inc. stock stands up against its competitors. Click into any of the below tickers to see their stock grades for value, momentum, quality and EPS revisions.

Generate Biomedicines, Inc. (GENB) Competitors

Companies similar to Generate Biomedicines, Inc. in the Biotechnology industry.

Company name	Ticker	Market Cap
Biohaven Ltd.	BHVN	$2.14Bil
Palvella Therapeutics, Inc.	PVLA	$2.16Bil
Sarepta Therapeutics, Inc.	SRPT	$2.08Bil
Vericel Corporation	VCEL	$2.23Bil
Zenas BioPharma, Inc.	ZBIO	$2.04Bil

Generate Biomedicines, Inc. Stock: Bottom Line

You can use the information about how Generate Biomedicines, Inc. is graded to determine if you should invest in this stock. However, you should decide whether Generate Biomedicines, Inc.’s stock is a buy, sell or hold based on a combination of grades, metrics, ratios and U.S. Securities and Exchange Commission (SEC) reports.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets—without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

So, if you’re still on the fence about whether Generate Biomedicines, Inc. is a buy, sell or hold, you can utilize AAII’s expansive and robust screening tools like A+ Investor to help with your decision.

A+ Investor adds to its qualitative teaching by giving you a powerful data suite that helps you whittle down investment decisions, find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.